Market LIVE
Published markets; coverage varies by country
Product profile · United States

TRULANCE

 ·  Patent Litigation & Settlement History ↓

IngredientPLECANATIDE
Application typeNDA
Application208745
Product001
Dosage formTABLET
RouteORAL
Strength3MG
Approval date2017-01-19
Marketing statusPrescription
Status event—
ApplicantSALIX
Product source

Current GenericRadar decision

Year2028
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typePATENT
Anchor date2028-01-30
Patent anchor2028-01-30
Exclusivity anchor2022-01-19
Protection date—
First Final ANDA—
Status event—

POST_ANCHOR_RIGHTS

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
70417862028-01-30DS —YNTRUE_DS
———
96103212031-09-15U U-2230NNU
———
96103212031-09-15U U-1999NNU
———
99190242031-09-15U U-2230NNU
———
99190242031-09-15U U-1999NNU
———
99252312031-09-15DP —NNDP
———
113193462032-03-01DP —NNDP
———
96160972032-08-20DP —NNDP
———
100116372034-06-05DS —NNDP
———
111425492034-06-05DP —NNDP
———
118345212034-06-05DP —NNDP
———
121460032034-06-05DP —NNDP
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-764—2021-01-24Historical Orange Book exclusivity; scope and start date not independently established————Source
NCE—2022-01-19FDA historical NCE 5-year new chemical entity exclusivity. Active-moiety-wide protection against covered follow-on NDA/ANDA applications; not indication-specific. Statutory exceptions or waivers are not excluded by this categorization.YY——Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
REGULATORY_STATUS2028-01-30CANONICAL_DECISIONPOST_ANCHOR_RIGHTSSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

Event datePartyEvent Licensed entryEvidenceSource
2026-04-03 MSN SETTLEMENT Not disclosed REVIEW —
Entry date undisclosed